Abstract
Lysophosphatidylcholine (LPC) is a bioactive proinflammatory lipid generated by pathological activities. LPC is also a major phospholipid component of oxidized low-density lipoprotein (Ox-LDL) and is implicated as a critical factor in the atherogenic activity of Ox-LDL. LPC is believed to play an important role in atherosclerosis and inflammatory diseases by altering various functions in a number of cell-types, including endothelial cells, smooth muscle cells, monocytes, macrophages, and T-cells. LPC activates several second messengers -- including protein kinase C, extracellular-signal-regulated kinases, protein tyrosine kinases, and Ca2+ -- implicating the engagement of transduction mechanisms in its observed actions. Moreover, recent evidence suggests that in several cell-types, cloned orphan G-protein-coupled receptors may serve as the specific receptors via which LPC modulates second messenger pathways (although LPC may not be a direct ligand of such receptors). In addition, current evidence suggests that LPC impairs the endothelium-dependent relaxations mediated by endothelium-derived relaxing factors and directly modulates contractile responses in vascular smooth muscle. However, despite all this, and although elevated levels of LPC have been linked to the cardiovascular complications associated with atherosclerosis, ischemia, and diabetes, the precise pathophysiological roles played by LPC in several states remain to be established. In this review, we focus in some detail on the entirety of the signal-transduction system for LPC, its pathophysiological implications, and the vascular abnormalities associated with it.
Keywords: Atherosclerosis, inflammatory, endothelial dysfunction, LPC, vascular tone, signal transduction
Current Medicinal Chemistry
Title: Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Volume: 14 Issue: 30
Author(s): Takayuki Matsumoto, Tsuneo Kobayashi and Katsuo Kamata
Affiliation:
Keywords: Atherosclerosis, inflammatory, endothelial dysfunction, LPC, vascular tone, signal transduction
Abstract: Lysophosphatidylcholine (LPC) is a bioactive proinflammatory lipid generated by pathological activities. LPC is also a major phospholipid component of oxidized low-density lipoprotein (Ox-LDL) and is implicated as a critical factor in the atherogenic activity of Ox-LDL. LPC is believed to play an important role in atherosclerosis and inflammatory diseases by altering various functions in a number of cell-types, including endothelial cells, smooth muscle cells, monocytes, macrophages, and T-cells. LPC activates several second messengers -- including protein kinase C, extracellular-signal-regulated kinases, protein tyrosine kinases, and Ca2+ -- implicating the engagement of transduction mechanisms in its observed actions. Moreover, recent evidence suggests that in several cell-types, cloned orphan G-protein-coupled receptors may serve as the specific receptors via which LPC modulates second messenger pathways (although LPC may not be a direct ligand of such receptors). In addition, current evidence suggests that LPC impairs the endothelium-dependent relaxations mediated by endothelium-derived relaxing factors and directly modulates contractile responses in vascular smooth muscle. However, despite all this, and although elevated levels of LPC have been linked to the cardiovascular complications associated with atherosclerosis, ischemia, and diabetes, the precise pathophysiological roles played by LPC in several states remain to be established. In this review, we focus in some detail on the entirety of the signal-transduction system for LPC, its pathophysiological implications, and the vascular abnormalities associated with it.
Export Options
About this article
Cite this article as:
Matsumoto Takayuki, Kobayashi Tsuneo and Kamata Katsuo, Role of Lysophosphatidylcholine (LPC) in Atherosclerosis, Current Medicinal Chemistry 2007; 14 (30) . https://dx.doi.org/10.2174/092986707782793899
DOI https://dx.doi.org/10.2174/092986707782793899 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Topics in Medicinal Chemistry Development of Immunopharmacotherapy Against Drugs of Abuse
Current Drug Discovery Technologies Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Echocardiogram versus Cardiac Magnetic Resonance Imaging for the Diagnosis of Non-compaction Cardiomyopathy – A Case Report
New Emirates Medical Journal Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot topic: The Inflammation Paradigm in Cardiovascular Disease (Guest Editor: Guha Krishnaswamy)]
Cardiovascular & Hematological Disorders-Drug Targets Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry